Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.